Drugs / Tyroserleutide
last change Jun 2019 re-read 2 minutes ago

Tyroserleutide

Developed for
hepatocellular carcinoma

Trials 0

Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03516448 Comparator Mar → Jun 2016 hepatocellular carcinoma Shenzhen Kangzhe Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 3 NCT01489566 Comparator Jul 2011 → Mar 2013 hepatocellular carcinoma Shenzhen Kangzhe Pharmaceutical Co., Ltd. Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Tyroserleutide ClinicalTrials.gov intervention name — accepted as the source's own label NCT03516448
1

NCT01489566

Route Intravenous “6mg/d, 5days,ivgtt” NCT03516448